Opens in a new tab

NimoTest® Fetal RHD qPCR kit

NIMoTest Fetal RHD qPCR kit

NIMoTest® Fetal RHD qPCR kit is a kit for determining the fetal RHD genotype from maternal plasma. It is intended for the monitoring of RhD-negative pregnant women to guide anti-RhD immunoprophylaxis and adapt the monitoring of immunised women.

Detailed description

The kit is designed for duplex quantitative PCR (pPCR) amplification of exons 5 and 7 of the RHD gene in circulating cell-free fetal DNA (cffDNA) samples obtained from the maternal plasma of non-immunised RhD-negative pregnant women. Results are interpreted by analysing the Ct curves using NIMoSoft® software.

Operating principle

The kit is designed to amplify specific regions of exons 5 and 7 of the RHD gene by pPCR, with a duration of approximately 1 hour from the extraction of the cffDNA (cell-free fetal DNA) present in maternal plasma. It includes a small extraction control (EC) that must be added to the plasma before lysis to validate the extraction process and verify the absence of PCR inhibitors. Results are interpreted using NIMoSoft® analysis software.
NIMoTest Fetal RHD qPCR kit workflow

Clinical applications

It is intended for determining the fetal RHD genotype from the maternal plasma of non-immunised RhD-negative pregnant women as part of non-invasive biological prenatal diagnosis. It supports decisions regarding the administration of anti-D prophylaxis only in pregnancies with an RhD-positive fetus to control the risk of fetal and neonatal haemolytic disease associated with anti-RhD. Indicated for use from week 11 of pregnancy.

Key aspects and benefits

Multiplex detection of exons 5 and 7 of the RhD gene with ready-to-use reagents.
Includes an extraction control (small DNA fragment) to validate extraction and the absence of inhibitors.
Provides a simplified workflow.
Simplified NIMoTest workflow
Includes NIMoSoft analysis software for complete traceability, validation, interpretation and LIMS integration.
Enables results to be obtained in approximately 1 hour from DNA extraction.

Technology used

Validated with QuantStudio 7, LightCycler 480 II, M2000rt and qTower3 instruments. Validated with extraction methods including MagNAPure 96, MagNA Pure 24, MagPurix, LabTurbo-24 and Chemagic 360d.

Intended users

Immunohaematology laboratories, blood banks and transfusion services interested in fetal RhD genotyping in non-immunised RhD-negative pregnant women.

Additional considerations

DNA extraction is critical due to the low concentration of cffDNA in maternal plasma. The test is only suitable from week 11 of pregnancy. Heparin may inhibit PCR; the validated starting material is plasma obtained from EDTA blood.
Presentation details
Kit size: 21 samples per 96-reaction kit to allow testing in triplicate and the extraction control.
Reference number: NIMRHDQ96.
Includes a positive control, negative control and extraction control.

Area:

Hematology
Consult our experts

Google reCaptcha: Invalid site key.

Related products

FUSIONPlex™ Heme v3 & Pan-Heme v2

RNA-based next-generation sequencing solution for the analytically sensitive identification of known and novel gene fusions, splicing variants, exon-skipping events, SNVs/Indels and gene expression in haematological malignancy research. FUSIONPlex Pan-Heme v2 provides broad coverage of 218 genes associated with haematological malignancies, while FUSIONPlex Heme v3 provides more focused coverage of 121 genes targeting alterations frequently found…
Archer Dx
Next Generation Sequencing (NGS)

Tapestri™

The Tapestri® platform enables the simultaneous integration of three biological dimensions from the same individual cell: DNA, RNA and surface proteins. This unprecedented multi-omics capability provides a direct and functional view of how specific genetic alterations (genotype) shape transcriptional expression and protein behaviour (phenotype), without the need to reconcile data from separate platforms. Conventional high-throughput…
Mission Bio
Single cell Sequencing

Violet 3.0 & QF-Pro® Technology

Conventional spatial biology reveals where proteins are; Violet 3.0 and QF-Pro® technology reveal what they are doing. Most current proteomic assays are limited to measuring molecular expression levels, overlooking whether proteins are actually activated or interacting with one another. In critical fields such as immuno-oncology, neurobiology and drug development, the relationship between expression and the…
Hawk Biosystem
Functional Assay

Beacon® Optofluidic Suite

The Beacon® Optofluidic Suite represents an absolute revolution in cell biology and biotherapeutic development. By synergistically integrating advanced microfluidics, precision optics, optoelectronics and artificial intelligence, this platform enables the isolation, culture, characterization and recovery of thousands of individual cells in a fully automated manner and in real time. Unlike traditional static or destructive methodologies, Bruker’s…
Bruker
Functional Assay